CTI BioPharma announces completion of rolling submission of New Drug Application (NDA) for pacritinib in myelofibrosis patients with severe thrombocytopenia

The NDA for this investigational oral kinase inhibitor with specificity for JAK2, IRAK1, and CSF1R is based upon available data from the completed Phase 3 PERSIST-1 and PERSIST-2 trials and the Phase 2 PAC203 trials in this population with limited treatment options.

Source:

Biospace Inc.